The Stock Of The Week: Novavax Inc. (NVAX)

As of Thursday close, Novavax Inc.’s (NASDAQ:NVAX) stock was down -$0.36, moving down -4.31 percent to $8.00. The average number of shares traded per day over the past five days has been 8,140,020 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.23 fall in that time frame. In the last twenty days, the average volume was 10,277,890, while in the previous 50 days, it was 7,717,076.

Since last month, NVAX stock retreated -4.71%. Shares of the company fell to $6.84 on 08/09/23, the lowest level in the past month. A 52-week high of $36.19 was reached on 01/18/23 after having rallying from a 52-week low of $5.61. Since the beginning of this year, NVAX’s stock price has dropped by -22.18% or -$2.28, and marked a new high 6 times. However, the stock has declined by -77.89% since its 52-week high.

NVAX stock investors should be aware that Novavax Inc. (NVAX) stock had its last reported insider trading activity 175 days ago on Mar 10. Glenn Gregory M, the President, R&D of the company, purchased of 1,000 shares for $6.50 on Mar 10. It resulted in a $6,500 investment by the insider. Glenn Gregory M added 2,000 shares at an average price of $7.04 on Mar 07. The insider now owns 13,473 shares following the transaction. On Mar 06, President, R&D Glenn Gregory M bought 3,000 shares at $7.48 apiece. The transaction was valued at $22,454.

Financial Health

In the three months ended June 29, Novavax Inc.’s quick ratio stood at 0.70, while its current ratio was 0.70, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 55.80% percent. In the year ended June 29, EBITDA margin amounted to -31.07%, whereas operating margins totaled -39.30%. Based on annual data, NVAX earned $1.08 billion in gross profit and brought in $1.98 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 769.90%. Return on equity (ROE) for the past 12 months was 82.30%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NVAX’s revenue rose 56.19% to $80.95 million during the quarter, while net income inched up to $424.43 million. While analysts expected Novavax Inc. to report -$1.39 quarterly earnings, the actual figure was $0.58 per share, beating the consensus estimate by 141.70%. During the quarter, the company generated $65.52 million in EBITDA. The liabilities of Novavax Inc. were 2.44 billion at the end of its most recent quarter ended June 29, and its total debt was $237.33 million. The value of shareholders’ equity is $94.4 million.

Technical Picture

This quick technical analysis looks at Novavax Inc.’s (NVAX) price momentum. With a historical volatility rate of 107.86%, the RSI 9-day stood at 48.49% on 31 August.

With respect to its five-day moving average, the current Novavax Inc. price is down by -2.79% percent or -$0.23. At present, NVAX shares trade -2.79% below its 20-day simple moving average. However, the stock is currently trading approximately +7.53% above its SMA50 and -68.05% below its SMA200.

Stochastic coefficient K was 47.33% and Stochastic coefficient D was 49.82%, while ATR was 0.69. Given the Stochastic reading of 38.93% for the 14-day period, the RSI (14) reading has been calculated as 49.67%. As of today, the MACD Oscillator reading stands at -0.17, while the 14-day reading stands at 0.25.

Analyst Ratings

B. Riley Securities upgraded its rating on Novavax Inc. (NASDAQ: NVAX) to a Buy in a note to investors on August 09, 2023. The analysts firm previously had a Neutral rating on the stock.Novavax Inc. (NVAX) has been rated Hold by analysts. According to 1 brokerage firm, NVAX is a sell, and 1 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Novavax Inc. stock as buy, with 3 recommending it as overweight.

With a median target price of $15.00, the current consensus forecast for the stock is $5.00 – $38.00. Based on these forecasts, analysts predict Novavax Inc. (NVAX) will achieve an average price target of $20.60.

Most Popular

Related Posts